Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression.

Autor: Geyer JT; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA jut9021@med.cornell.edu., Margolskee E; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA., Krichevsky SA; Department of Medicine, Weill Cornell Medicine, New York, NY, USA., Cattaneo D; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy., Boiocchi L; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Ronchi P; IRCCS San Raffaele Scientific Institute, Milan, Italy., Lunghi F; IRCCS San Raffaele Scientific Institute, Milan, Italy., Scandura JM; Department of Medicine, Weill Cornell Medicine, New York, NY, USA., Ponzoni M; IRCCS San Raffaele Scientific Institute, Milan, Italy., Hasserjian RP; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Gianelli U; Division of Pathology, Department of Pathophysiology and Transplantation, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy., Iurlo A; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy., Orazi A; Department of Pathology, Texas Tech University, El Paso, TX, USA.

Publikováno v: Haematologica [Haematologica] 2020 May; Vol. 105 (5), pp. e221-e224. Date of Electronic Publication: 2019 Sep 19.